News | February 25, 2026
UK nod to first-ever drug specifically for non-cystic fibrosis bronchiectasis
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
